Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer

INTRODUCTION: Patients with metastatic hormone sensitive prostate cancer (mHSPC) have traditionally been treated with androgen deprivation therapy (ADT). Recently, there has been a demonstration of a survival benefit with the addition of docetaxel to ADT from three large randomized controlled trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Shenoy, Niraj, Kohli, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054654/
https://www.ncbi.nlm.nih.gov/pubmed/27843206
http://dx.doi.org/10.4103/0970-1591.191234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054654/
https://www.ncbi.nlm.nih.gov/pubmed/27843206
http://dx.doi.org/10.4103/0970-1591.191234

Ejemplares similares